LAUSR

We thank Drs. Khunte and Malhotra for their comments on our study.1 As we have stated in the Discussion section of our article, onset-to-treatment times were not available for our analysis. But we agree that your hypothesis could certainly be true. We are not sure where you saw the increased hemorrhage rate reported in our artcicle because data on intracranial hemorrhages were unverifiable in the SITS-TBY registry and could not be evaluated for our study.1 Furthermore, the MR CLEAN Registry group published an article recently, which “found no evidence of an association of prior antiplatelet therapy with the risk of symptomatic intracranial hemorrhage after endovascular treatment, nor on functional outcome, reperfusion, or mortality.”2